PT1105728E - Modulacao de proteinas - Google Patents

Modulacao de proteinas

Info

Publication number
PT1105728E
PT1105728E PT99943759T PT99943759T PT1105728E PT 1105728 E PT1105728 E PT 1105728E PT 99943759 T PT99943759 T PT 99943759T PT 99943759 T PT99943759 T PT 99943759T PT 1105728 E PT1105728 E PT 1105728E
Authority
PT
Portugal
Prior art keywords
protein
methods
compound
lineage kinase
kinase protein
Prior art date
Application number
PT99943759T
Other languages
English (en)
Portuguese (pt)
Inventor
Ernest Knight Jr
Craig A Dionne
Maroney Anna
Kevin M Walton
Neff Nicola
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of PT1105728E publication Critical patent/PT1105728E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
PT99943759T 1998-08-26 1999-08-18 Modulacao de proteinas PT1105728E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9798098P 1998-08-26 1998-08-26

Publications (1)

Publication Number Publication Date
PT1105728E true PT1105728E (pt) 2005-07-29

Family

ID=22266038

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99943759T PT1105728E (pt) 1998-08-26 1999-08-18 Modulacao de proteinas

Country Status (25)

Country Link
EP (1) EP1105728B1 (da)
JP (1) JP2002523780A (da)
KR (1) KR100700028B1 (da)
CN (3) CN1206535C (da)
AT (1) ATE293254T1 (da)
AU (1) AU765637B2 (da)
BG (1) BG105360A (da)
BR (1) BR9913190A (da)
CA (1) CA2339539A1 (da)
CZ (1) CZ2001701A3 (da)
DE (1) DE69924738T2 (da)
DK (1) DK1105728T3 (da)
EA (2) EA006648B1 (da)
ES (1) ES2241316T3 (da)
HK (1) HK1037722A1 (da)
HU (1) HUP0103079A3 (da)
NO (1) NO20010389L (da)
NZ (1) NZ509612A (da)
PL (1) PL346246A1 (da)
PT (1) PT1105728E (da)
SK (1) SK2542001A3 (da)
TR (2) TR200400635T2 (da)
UA (1) UA74772C2 (da)
WO (1) WO2000013015A1 (da)
ZA (1) ZA200100835B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
BR0113266A (pt) * 2000-08-11 2005-01-04 Cephalon Inc Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003052395A (ja) * 2001-08-09 2003-02-25 Japan Tissue Engineering:Kk 移植適正判定方法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2240783A2 (en) * 2008-02-04 2010-10-20 Galapagos N.V. Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases.
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
AU2015202365B2 (en) * 2008-10-22 2016-11-24 Genentech, Inc. Modulation of axon degeneration
KR20110081862A (ko) * 2008-10-22 2011-07-14 제넨테크, 인크. 축삭 변성의 조절
CN102573855A (zh) * 2009-10-22 2012-07-11 霍夫曼-拉罗奇有限公司 轴突变性的调节
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
US9539259B2 (en) 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN109060472A (zh) * 2018-07-20 2018-12-21 上海市农业科学院 一种适于荧光染色的草菇菌褶组织切片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Also Published As

Publication number Publication date
HUP0103079A3 (en) 2004-03-01
BR9913190A (pt) 2001-12-11
ES2241316T3 (es) 2005-10-16
UA74772C2 (en) 2006-02-15
NO20010389D0 (no) 2001-01-23
SK2542001A3 (en) 2002-06-04
EA006648B1 (ru) 2006-02-24
EP1105728B1 (en) 2005-04-13
ZA200100835B (en) 2002-06-26
DE69924738T2 (de) 2006-03-02
NO20010389L (no) 2001-04-02
CZ2001701A3 (cs) 2002-04-17
BG105360A (bg) 2001-10-31
CN1314999A (zh) 2001-09-26
CA2339539A1 (en) 2000-03-09
KR100700028B1 (ko) 2007-03-27
ATE293254T1 (de) 2005-04-15
TR200100589T2 (tr) 2001-07-23
NZ509612A (en) 2003-10-31
WO2000013015A1 (en) 2000-03-09
HUP0103079A2 (hu) 2001-12-28
KR20010103573A (ko) 2001-11-23
EP1105728A1 (en) 2001-06-13
TR200400635T2 (tr) 2005-10-21
EA200100278A1 (ru) 2002-06-27
HK1037722A1 (en) 2002-02-15
CN1589788A (zh) 2005-03-09
AU765637B2 (en) 2003-09-25
AU5679399A (en) 2000-03-21
DE69924738D1 (de) 2005-05-19
JP2002523780A (ja) 2002-07-30
EA200500934A1 (ru) 2006-04-28
DK1105728T3 (da) 2005-08-08
CN1206535C (zh) 2005-06-15
PL346246A1 (en) 2002-01-28
WO2000013015A8 (en) 2000-05-11
CN1879617A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
PT1105728E (pt) Modulacao de proteinas
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
ATE391177T1 (de) Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
AU2002248180A1 (en) Non-apoptotic forms of cell death and methods of modulation
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
WO2004109290A3 (en) Methods for identifying modulators of kinesin activity
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use
WO2000000510A1 (en) MODULATORS OF THE GROWTH FACTOR